

Minutes of the Supplier Advisory Panel Meeting Wednesday 11 March 2026

This meeting was held online from 9am to 10am.

Present:

Members:

Liz Naylor (AstraZeneca)
Michaela Lion (AbbVie)
Kate King (Medtronic)
Francis Lawes (Pfizer)
Angela Pantano (Roche)
Lindsay Ancelet (GSK)
Matt Needham (Roche)

Pharmac staff attendees:

Jannel Fisher (Reset Programme Manager)
Claire Pouwels (Manager, Pharmaceutical Funding)
Caro De Luca (Manager Expert Advisory)
Ben Campbell-Macdonald (Manager, Pharmaceutical Assessment)
Hendrik Furstenu (Programme Advisor)

Apologies:

Kylie Earle (Sanofi)

1. Karakia and welcome

The meeting was opened by the chair.

2. Minutes of previous meeting

Minutes of the previous meeting minutes were approved.

- Moved by: Liz
- Seconded by: Lindsay

3. Action items

- Action items were noted.

4. Interest register

- No new interest declarations.
- Members should include their employment details for completeness.

Action: Members to send updated conflict of interest information.

5. Discussion of draft future blueprint

Pharmac shared its new vision and strategic priorities, providing members with additional context for the proposed four-year improvement programme and the direction of future change.

A draft blueprint intended to support delivery of the improvement programme was discussed. Members engaged constructively with the proposed approach and sought greater clarity on several aspects of the programme, including how success would be defined and measured.

Members also raised questions about the sequencing, timing, and feasibility of the proposed improvements, how medical devices would be integrated, and the potential implications for budgets that sit outside Pharmac's direct control.

Discussion emphasised the importance of establishing a clear and shared goal to guide the improvement programme. Members highlighted the need for greater timeliness and predictability across Pharmac's processes.

Members were invited to continue providing feedback on the draft blueprint. This feedback will be collated and shared with the panel at a later stage.

6. General business

Chair and meeting arrangements were discussed. The Chair role includes responsibility for reviewing meeting summaries. Meetings are expected to occur approximately every four weeks, with flexibility to meet more frequently if required.

Members also noted several potential areas for future discussion, including streamlining assessment processes, application acceptance criteria, and clarifying timeframes and sequencing for improvements.

Close of meeting at 10am.

Next meeting: 8 April 2026